Exchange: NASDAQ·Updated 07:59 PM EST

CLRB News

News
all
press releases
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
Cellectar Biosciences (CLRB) Upgraded to Buy: Here's What You Should Know
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
More News
Here is how Centene (CNC) and Cellectar Biosciences, Inc. (CLRB) have performed compared to their sector so far this year.
Zacks
The biotech firm reported strong Phase 2 trial results for a blood cancer treatment, along with a $140 million fundraise to support the next stages of the trial.
Stocktwits
Biotech and pharma markets are leading the way in a sharply selective environment at midday, where clinical data, insider conviction, and platform scalability are driving outsized moves while weaker narratives get left behind. $NTHI, $POET, $SDOT, $BDRX, $CLRB, $DOCN, $FSLY, $EWTX, $BLDP
24-7 Market News
Cellectar releases Phase 2b CLOVER WaM data showing strong response rates and durability, alongside $140 million financing.read more...
Benzinga
$CLRB, $NTHI, $BLZE, $DGXX, $VRDN, $CYTK are among today's leading stocks
24-7 Market News
The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.
Stocktwits
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks

Advertisement|Remove ads.